VECTURA LIMITED

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Comparison of VR647 and Conventionally Nebulized Budesonide in Healthy Volunteers and Adult Asthma Subjects

Phase 1

Completed

Conditions: Asthma

Interventions: Combination Product: VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece
Combination Product: 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece
Combination Product: 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask
Combination Product: VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask
Combination Product: 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask
Combination Product: 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece

First Posted Date: 2019-07-25

Last Posted Date: 2019-07-25

Lead Sponsor: Vectura Limited

Target Recruit Count: 34

Registration Number: NCT04032834

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Celerion, Tempe, Arizona, United States

A Methodology Trial Using the VR647 Inhalation System in Pediatric Subjects Who Have Previously Received Inhaled Therapy

Early Phase 1

Completed

Conditions: Cough
Wheezing

Interventions: Combination Product: VR647 Inhalation System + VR647 Smart Card 3 Secs
Combination Product: VR647 Inhalation System + VR647 Smart Card 2 Secs
Combination Product: VR647 Inhalation System + VR647 Smart Card 4 Secs

First Posted Date: 2019-07-08

Last Posted Date: 2019-07-08

Lead Sponsor: Vectura Limited

Target Recruit Count: 41

Registration Number: NCT04011709

Locations: 🇺🇸
Clinical Research Institute, Inc, Plymouth, Minnesota, United States
🇺🇸
North Carolina Clinical Research, Raleigh, North Carolina, United States
🇺🇸
Allergy & Asthma Associates of Southern California, Mission Viejo, California, United States

and more 2 locations

A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma

Phase 1

Completed

Conditions: Wheezing
Reactive Airway Disease
Mild Asthma

Interventions: Combination Product: VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System
Combination Product: 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer

First Posted Date: 2018-02-05

Last Posted Date: 2019-10-21

Lead Sponsor: Vectura Limited

Target Recruit Count: 17

Registration Number: NCT03421730

Locations: 🇺🇸
Vectura Study Site 0001, Tulsa, Oklahoma, United States
🇺🇸
Vectura Study Site 0003, Colorado Springs, Colorado, United States
🇺🇸
Vectura Study Site 0002, Raleigh, North Carolina, United States

An Evaluation of VR942 in Healthy Volunteers and Patients With Mild Asthma

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: VR942 delivered via a Vectura Dry Powder Inhaler
Drug: Placebo delivered via a Vectura Dry Powder Inhaler

First Posted Date: 2015-06-17

Last Posted Date: 2016-12-21

Lead Sponsor: Vectura Limited

Target Recruit Count: 85

Registration Number: NCT02473939

Locations: 🇬🇧
Vectura Study Site, London, United Kingdom

Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: VR506

First Posted Date: 2012-11-01

Last Posted Date: 2020-04-21

Lead Sponsor: Vectura Limited

Target Recruit Count: 197

Registration Number: NCT01720069

Locations: 🇩🇪
Vectura Clinical Trial Site 03008, Donaustauf, Germany
🇷🇴
Vectura Clinicl Trial Site 07011, Timis, Romania
🇺🇦
Vectura Clinical Trial Site 06011, Vinnitsa, Ukraine

and more 74 locations

Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: VR506

First Posted Date: 2011-11-16

Last Posted Date: 2020-04-21

Lead Sponsor: Vectura Limited

Target Recruit Count: 374

Registration Number: NCT01472757

Locations: 🇺🇸
Vectura Clinical Trial Site 10009, Missoula, Montana, United States
🇺🇸
Vectura Clinical Trial Site 10028, Medford, Oregon, United States
🇵🇭
Vectura Clinical Trial Site 31003, Iloilo City, Philippines

and more 79 locations

Home Terms & Conditions Privacy Policy